Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

CONCLUSION: Co-administration of doses of remogliflozin etabonate (500 mg BID or 750 mg BID) greater than the commercial dose (100 mg BID) with metformin (2000 mg BID) was shown to be safe and effective during the observation period.TRIAL REGISTRATION: ClinicalTrials.gov , NCT00519480 . Registered:22 August 2007.PMID:34120651 | DOI:10.1186/s40360-021-00502-0

Source: BMC Pharmacology and Toxicology - June 14, 2021 Category: Drugs & Pharmacology Authors: Robert Dobbins Elizabeth K Hussey Robin O'Connor-Semmes Susan Andrews Wenli Tao William O Wilkison Bentley Cheatham Katare Sagar Barkate Hanmant Source Type: research